Message Board

Respected readers, authors and reviewers, you can add comments to this page on any questions about the contribution, review,        editing and publication of this journal. We will give you an answer as soon as possible. Thank you for your support!

Name
E-mail
Phone
Title
Content
Verification Code

Current Articles

2026, Volume 46,  Issue 6

Cover Catalogue
Reviews
Research progress on the effects and mechanisms of plateau hypoxia on drug metabolism
LI Qian, WANG Rong, YANG Feng, WANG Xiaofeng, YIN Dongfeng
2026, 44(6): 275-279. doi: 10.12206/j.issn.2097-2024.202403018
Abstract(6902) HTML (1056) PDF (892KB)(17)
Abstract:
The plateau region is known for its unique environmental characteristics of low oxygen, low pressure, strong radiation, cold and dryness. Under the low oxygen environment, human physiological functions and drug metabolism are significantly affected. In order to gain a deeper understanding of drug metabolism in the plateau hypoxic environment and to guide the rational use of drugs in the plateau region, the effects of plateau hypoxia on drug metabolism were reviewed in this paper, which focused on changes in metabolic profiles, enzyme activity and expression, and probed the relevant mechanisms in depth.
Original articles
Evaluation of anticancer activity of marine microbial secondary metabolites based on intrahepatic cholangiocarcinoma organoid models and study on its induction of cancer cell apoptosis
FAN Xiaoting, MAO Zhifan, LIU Jian, YANG Fan, LIN Houwen
2026, 44(6): 280-288, 312. doi: 10.12206/j.issn.2097-2024.202603003
Abstract(391) HTML (209) PDF (4721KB)(4)
Abstract:
  Objective  To investigate the anti-intrahepatic cholangiocarcinoma (ICC) activity and mechanism of 2-heptyl-3-hydroxy-4(1H)-quinolone (PQS), a secondary metabolite of polar marine microorganisms.   Methods  Patient-derived organoid (PDO) models were established using intrahepatic cholangiocarcinoma (ICC) tumor tissues obtained from Renji Hospital, Shanghai Jiao Tong University School of Medicine. Hematoxylin and eosin (HE) staining was performed to assess the histomorphological characteristics of both patient ICC tissues and corresponding PDOs. Immunohistochemistry (IHC) was employed to evaluate CYP3a expression in patient ICC tissues and PDOs. The antiproliferative activity of PQS against stably passaged PDOs was determined using an adenosine triphosphate (ATP)-based bioluminescence assay, and dose-response curves were fitted to calculate the half-maximal inhibitory concentration (IC50) for assessing the anti-ICC efficacy of PQS. In the human intrahepatic cholangiocarcinoma RBE cell model, the effects of PQS on RBE cell proliferation were evaluated by the cell counting kit-8 (CCK-8) assay; colony formation capacity was assessed by the plate colony formation assay; cell cycle distribution and apoptosis were analyzed by flow cytometry; and the protein expression levels of cyclin-dependent kinase 2(CDK2), CDK4, RelA(p65), and nuclear factor-κB1(p50) were detected by Western blotting.   Results  Two ICC PDO models were successfully established. Histomorphological observation revealed that the PDO tissues after serial passaging exhibited morphological features essentially consistent with the corresponding patient ICC tissues, both presenting as cystic vesicle-like structures. Immunohistochemical analysis demonstrated that CYP3a was expressed in both PDO tissues and patient ICC tissues. ATP-based bioluminescence assay results indicated that PQS effectively suppressed ATP content in PDO tissues, with a fitted dose-response curve yielding an IC50 value of 2.49 µmol/L. In the RBE cell model, PQS inhibited RBE cell viability in a concentration-dependent manner, and the fitted dose-response curve yielded an IC50 value of 1.05 µmol/L. Furthermore, PQS at concentrations of 1, 2, and 4 µmol/L significantly suppressed colony formation of RBE cells, arrested the cell cycle at the S phase, induced apoptosis, and downregulated the expression of proteins associated with the NF-κB signaling pathway.   Conclusion  ICC PDO models were successfully established, confirming the anti-ICC activity of PQS. PQS inhibited RBE cell proliferation, potentially via the NF-κB signaling pathway, by arresting the cell cycle at the S phase and inducing apoptosis of RBE cells
The hypolipidemic function and hepatic protective effects of Xuetong capsules
HE Lin, CHENG Yanqiong, ZHAO Juanjuan, LU Huilan, YANG Jun, CHEN Fangjian
2026, 44(6): 289-295, 321. doi: 10.12206/j.issn.2097-2024.202502015
Abstract(9103) HTML (3553) PDF (3017KB)(58)
Abstract:
  Objective  To investigate the effects of Xuetong capsule on blood lipids and liver lesion in hyperlipidemic model animals.   Methods  Sixty ICR mice were randomly divided into six groups. The normal control group was fed with normal diet, the other groups were fed with high-fat diet to induce hyperlipidemia. After four weeks feeding, the three groups were given low, middle, and high doses of Xuetong capsules (0.5, 1.0, and 2.0 g/kg) by gavage, and the positive drug control group was given atorvastatin calcium (1.5 mg/kg) by gavage. The model group was given solvent (0.5% carboxymethyl cellulose sodium). After treatment for 8 weeks, the body weight, organ index, blood lipids, blood glucose and liver function index were measured. The liver oil red staining was used to determine the lipid droplet content, and quantitative PCR was used to detect the expression of inflammatory factors TNF-α, IL-6, and IL-1β.   Results  The body weight, the weight of liver and spleen were significantly increased by high-fat diet. High-fat diet increased the organ indexes of the liver and spleen, the degree of liver oil red staining, and also significantly increased the levels of glucose, triglyceride (TG), cholesterol (CHOL), and low-density lipoprotein cholesterol (LDL-C) in serum. Compared with the model group, the level of TG has no significant change in low, middle and high doses groups. The level of CHOL in serum was reduced by Xuetong capsule with a dose dependent manner. There were significant difference between the model group and middle, high doses groups. The results of LDL-C were similar, the level of LDL-C was significantly reduced by middle and high doses groups [middle dose (0.55±0.21) mmol/L, high dose (0.52±0.22) mmol/L vs (0.81±0.29) mmol/L in model group, P<0.05]. Compared with the normal control, there was no significant difference in HDL-C levels between the high-fat model and each drug-treated group. Liver function showed that Xuetong capsules significantly reduced the degree of liver oil red staining and decreased the level of alanine aminotransferase (ALT) induced by high-fat diet. The body weight, the weight and organ indexes of liver and spleen were significantly reduced by positive drug control group. The levels of CHOL, LDL-C, and TG, and the degree of liver oil red staining were also significantly reduced in positive drug control group. Further studies have shown that high dose of Xuetong capsules significantly reduced the expression of TNF-α and IL-6 induced by high-fat diet (P<0.05), while the reduction of IL-1β was not so significant (P>0.05).   Conclusion  Xuetong capsules significantly reduced the body weight of animals with high fat, liver size, fat deposition, inflammatory damage and also significantly reduced blood lipid CHOL and LDL-C levels and transaminase elevation. The above effects may be related to Xuetong capsules reducing the expression of inflammatory factors such as TNF-α and IL-6 in the liver.
Mechanism of Jianfu mixture in the treatment of erectile dysfunction based on network pharmacology analysis, molecular docking and in vitro experimental validation
YANG Yantao, YU Chao, ZHANG Zhihang, PAN Yujiong, HE Xiaofeng, XU Min
2026, 44(6): 296-305. doi: 10.12206/j.issn.2097-2024.202407013
Abstract(10109) HTML (1849) PDF (2174KB)(17)
Abstract:
  Objective  To explore the molecular mechanism of Jianfu mixture in the treatment of erectile dysfunction (ED) by network pharmacology and molecular docking techniques, and validate its core targets and mechanisms through in vitro experiments.   Methods  The active components and corresponding molecular targets of Jianfu mixture were searched by searching TCMSP and Batman-TCM databases, and the disease targets of ED were searched by using GeneCards database. Find the intersection of drug ingredient target and disease target. The interaction between intersected targets was described and analyzed by String database, and the analysis results were visualized by Cytoscape software to determine the core target and the corresponding active components. GO functional enrichment analysis and KEGG pathway enrichment analysis were performed for intersection targets; the core target within the intersection were found through MCODE plug-in on Cytoscape software and molecular docking was performed with the corresponding active ingredients. An endothelial dysfunction model was established by transfecting HUVECs with si-eNOS. Intervene with different concentrations of the Jianfu mixture for the model cells for 24 h. QPCR was used to detect mRNA expression of core targets (MAPK1, MAPK3, JUN, ESR1, MAPK8); Western blot was used to analyze protein expression (eNOS, JUN, p-JUN, MAPK, p-MAPK) and phosphorylation levels.   Results  144 effective active components and 168 active components target-disease targe intersection of Jianfu mixture were obtained. GO analysis revealed 200 5 biological processes, 151 molecular functions, and 63 cellular components. KEGG analysis yielded 181 pathways. 5 core targets including MAPK1, MAPK3, JUN, ESR1 and MAPK8 were screened out. The active components such as β-sitosterol, kaempferol, astapterocarpan had good binding affinity with the core target. In vitro experiments confirmed successful construction of the endothelial dysfunction model (eNOS expression significantly decreased after si-eNOS transfection). Jianfu mixture dose-dependently inhibited mRNA expression of MAPK1, MAPK3, JUN, ESR1, and MAPK8. Additionally, it reduced phosphorylation levels of JUN and MAPK, indicating inhibition of the JNK/c-Jun and ERK/MAPK signaling pathways to improve endothelial function.   Conclusion  Jianfu mixture treats ED by suppressing abnormal activation of multi-target signaling pathways (MAPK/JUN/ESR1), reducing endothelial apoptosis, and promoting NO synthesis. This mechanism aligns with the traditional Chinese medicine principle of “activating blood circulation, resolving stasis, tonifying Qi, and strengthening cardiovascular function.” The study provided molecular-level evidence for the therapeutic efficacy of Jianfu mixture in ED management.
Research reports
Visual analysis of domestic literature on traditional Chinese medicine herbal compresses by CiteSpace
WANG Mengxin, YU Lei, TAN Xiao
2026, 44(6): 306-312. doi: 10.12206/j.issn.2097-2024.202506001
Abstract(541) HTML (315) PDF (6064KB)(4)
Abstract:
  Objective  To visually analyze the research literature of traditional Chinese medicine (TCM) herbal compresses in China by CiteSpace software, sort out the development process and direction changes of research, reveal cutting-edge hotspots, predict research trends, and provide reference for in-depth research and application of TCM herbal compresses.  Methods  Literature related to TCM herbal compresses were retrieved from databases including China National Knowledge Infrastructure (CNKI), Wanfang Data Knowledge Service Platform, VIP Journal Integration Platform (VJIP), covering the period from September 1, 2002 to November 15, 2024. CiteSpace software was used for visualization analysis.   Results  A total of 508 documents were included, and the annual publication volume showed a fluctuating growth. The number of publications was higher in northern regions than in southern regions, with Jilin and Henan provinces being the majority. The institution with the highest number of publications was Changchun University of TCM. The authors with the highest number of publications were Xing Linbo and Hou GuiHong. Collaboration among authors and institutions was generally suboptimal, with limited cross-regional cooperation. The top three high-frequency keywords were nursing, (clinical) efficacy, and pain. The emerging keywords indicated that adverse reactions, clinical efficacy, and traditional Chinese medicine rubbing were hot topics in the study of Chinese medicine herbal compresses.   Conclusion  The research on TCM herbal compresses in China was in a steady development stage, with research hotspots focused on clinical efficacy observation and adverse reactions of multiple therapies combined. In the future, cross institutional cooperation and in-depth research need to be strengthened to promote further development in this field.
Medicine & Clinical
Practice and analysis of the simplified oral premedication protocol with paclitaxel liposome in patients of advanced gastric cancer
ZHONG Ling, CAO Jinfa, HE Miao, TIAN Jing
2026, 44(6): 313-316. doi: 10.12206/j.issn.2097-2024.202406047
Abstract(7604) HTML (2722) PDF (836KB)(25)
Abstract:
  Objective  To explore a feasible simplified premedication protocol for preventing hypersensitivity reactions to taxanes.   Methods  The electronic medical record system was used to search for data from 49 patients with advanced gastric cancer who received paclitaxel liposome treatment for the first time in the gastroenterology department of Shanghai Changhai Hospital from 2021-06-01 to 2024-06-30, including premedication protocols, allergic reactions, and other adverse reactions.   Results  Among 31 patients, the premedication regimen included oral dexamethasone 9 mg at 12 h and 6 h prior to liposomal paclitaxel, plus oral loratadine 10 mg and oral ranitidine 150 mg at 12 h prior to treatment. Among 18 patients, the regimen included oral dexamethasone 9 mg at 12 h and 6 h prior to treatment, and oral loratadine 10 mg at 12 h prior to treatment. None of the patients experienced allergic reactions. The incidence of other adverse reactions did not differ significantly between the two groups(P>0.05).   Conclusion   Based on literature and practice, a dual simplified premedication protocol of oral corticosteroids(GC)combined with oral H1 receptor blockers(H1RA)was proposed, which provided a new idea for doctors. Further clinical studies are needed to verify its effectiveness.
Pharmacy administration
The establishment and application of an online intelligent medication follow-up platform for outpatient patients
WANG Yushuang, LIU Yulong, QIU Ji
2026, 44(6): 317-321. doi: 10.12206/j.issn.2097-2024.202408025
Abstract(517) HTML (445) PDF (1251KB)(6)
Abstract:
  Objective  To promote rational drug use and improve the quality of outpatient pharmacy services by establishing an intelligent medication follow-up platform and carrying out online medication follow-up for outpatients.   Methods  The Internet and WeChat mini programs were used to establish an intelligent medication follow-up platform, and effective follow-up records were selected from June 1, 2023 to May 31, 2024 to analyze the results of patients' follow-up.   Results  The platform could automatically push follow-up messages to patients and supports the exchange of text, pictures, and voice communication between pharmacists and patients. A total of 613 patients were selected to participate in the follow-up. Thirteen blood glucose records and 17 blood pressure readings were uploaded, and 583 medication consultations were recorded.   Conclusion  This study tracked and understood the medication situation of outpatients through an intelligent medication follow-up platform. The platform was professional, intelligent, and convenient, which was conducive to improving the safety of patients' home medication and promoting reasonable medication.
Optimizing the whole-process quality control system of intravenous drug distribution center based on failure mode and effect analysis
WEI Wei, ZHANG Mingxia, ZHOU Yanping, YAN Lan, TIAN Peng, FENG Xia
2026, 44(6): 322-328. doi: 10.12206/j.issn.2097-2024.202504131
Abstract(5630) HTML (2300) PDF (1035KB)(34)
Abstract:
  Objective  To explore the application effect of a standardized management method based on failure mode and effect analysis (FMEA) in optimizing the whole-process quality control system of the intravenous admixture service (PIVAS).  Methods  The quality control management system of the PIVAS was optimized by establishing six quality control groups led by the head nurse, with full participation of pharmacy, nursing, and logistical staff, ensuring comprehensive coverage and traceability of all quality control links. Each group conducted risk priority number (RPN) scoring for potential failure modes in their respective quality control processes, and targeted improvement measures were formulated based on the scoring results. The RPN values of failure modes and quality control-related evaluation indicators before and after implementation were compared to achieve closed-loop management.   Results  After one year of management, the RPN values of the six major failure modes significantly decreased compared to those before implementation (P<0.05). The compounding error rate dropped to 0.13%, the dispensing error rate decreased to 0.95%, the compounding efficiency increased to 98%, the delivery time was shortened by 0.45 h per batch, the intervention rate for irrational prescriptions rose to 94.87%, satisfaction improved to 96.78%, and the participation rate of quality control personnel reached 95.36% (P<0.05).   Conclusion  FMEA-based identification of potential failure modes in the whole-process quality control system of the IVAS, combined with risk quantification and targeted interventions, significantly reduced high-risk failure modes, improved compounding accuracy and efficiency, and ensured the safety of clinical intravenous medication and the effectiveness of healthcare quality management.